February 2014 Patient Savings Program Use Analysis

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "February 2014 Patient Savings Program Use Analysis"

Transcription

1 Providing key policy setters and decision makers in the global health sector with unique and transformational insights into healthcare dynamics derived from granular analysis of information. February 2014 Patient Savings Program Use Analysis IMS Institute for Healthcare Informatics Patient Savings Program Impact Analysis 11 Waterview Boulevard, Parsippany, NJ 07054, USA

2 IMS Institute for Healthcare Informatics February 2014 Background A large number and variety of patient savings programs have been established over the past twenty years by pharmaceutical manufacturers in an effort to reduce financial barriers to patients and enable them to receive the medicines prescribed to them by healthcare professionals. This has occurred even as generic drugs have risen to comprise 84% of all dispended prescriptions in 2012 (see Exhibit 1). The extent to which these programs are used, the type of medicines typically involved, and the way in which patient savings programs are used to support patient treatment has not been well analyzed or documented. The purpose of this report is to summarize the findings of a study undertaken by IMS Health and which was funded by Pfizer, Inc. The interpretation of the study results and preparation of this summary was undertaken independently by a team from the IMS Institute for Healthcare Informatics which is part of IMS Health but operates separately and according to its own mission, research agenda and guiding principles 1. This research was conducted by the Institute independently and without industry or government funding. EXHIBIT 1 Generics share of total prescriptions 54% 57% 60% 63% 67% 72% 74% 78% 80% 84% 43% 46% 50% 54% 58% 63% 66% 70% 73% 77% 11% 11% 10% 9% 9% 9% 8% 8% 7% 7% Branded Generics Unbranded Generics Source: IMS Health, National Prescription Audit, Dec See page 11 of this report, or visit the IMS Institute website 2

3 Approach and Sources The analysis utilized IMS Health longitudinal anonymized patient-level prescription data as gathered from retail pharmacies. Coverage of all retail pharmacy transactions is estimated by IMS Health to be 74%, and 68% of individual prescriptions are able to be linked longitudinally at the patient level. This level of coverage provides comprehensive and detailed understanding of the 3.5 billion retail prescriptions filled through chain store, independent and food store retail pharmacies in Retail prescriptions filled through mail-order or specialty pharmacies are not included in this analysis. Prescriptions filled by patients using a co-pay card or voucher that are part of a Patient Savings Program are identified in the retail information provided by retail pharmacies and assigned to the specific Program under which they are filled. A minimum number of 100 unique patients is required for a Patient Savings Program to be included in this analysis. Prescriptions covered by third party commercial payers are included in this analysis. Prescriptions filled under a Patient Savings Program are included regardless of the level of deductible, co-insurance or co-payment that may have been required. Prescriptions reimbursed under Medicaid or Medicare Part D programs are not included as patient subsidies are not permitted under these programs. Methodology Retail prescriptions, as captured by the IMS Health National Prescription Audit and filled between November 1, 2011 and October 31, 2012, were included in this analysis. Patients are counted once only in this analysis for each Patient Savings Program under which they have filled one or more prescriptions. All of the prescriptions filled by that patient under the Patient Savings Program are included in the analysis. Patients filling prescriptions under multiple Patient Savings Programs are counted each time they use a different Patient Savings Program. Almost all of these programs are for branded pharmaceuticals, with only 23 of the 549 programs covering generic drugs. Analysis in this report is based on all programs. 2 IMS Institute for Healthcare Informatics, Declining Medicine Use and Costs: For Better or Worse? May

4 Findings Among the key findings regarding the use and impact of Patient Savings Programs are summarized in the following areas: Number and characteristics of Patient Savings Programs (see Exhibit 2) A total of 549 Patient Savings Programs were identified, covering medicines for the treatment of a range of disease areas, including dyslipidemia, asthma, diabetes and sleep disorders. A relatively small number of prescriptions are filled through Patient Savings Programs: only 1.2% of total prescriptions and 6.1% of branded prescriptions are filled through these programs during the time period studied. Of total prescriptions dispensed during the 12 month period studied, 80.4% were dispensed as generics, 18.4% were dispensed as brands and were not part of a Prescription Savings Program, while 1.2% were dispensed as part of a brand s Program. Over the course of the 12 month period, 14 million patients benefited from participation in these programs, of whom 90% used one program and 10% used multiple programs. EXHIBIT 2 Number and Characteristics of Patient Savings Programs Patient Savings Program (PSP) Prescription Usage PSP Programs Used By 14 Million Patients 1.2% 18.4% 10% 80.4% 90% Branded Non PSP Prescriptions Generic Non PSP Prescriptions Total Prescriptions using PSPs Used 1 Program Used More than 1 Program 4

5 TOP 10 PSP THERAPEUTIC AREAS Top Therapeutic Areas for Patient Savings Programs (see Exhibit 3) Patient Savings Programs are available for medicines used in the treatment of a broad range of large therapeutic areas, including cholesterol management, hypertension, asthma and diabetes, each of which affect millions of Americans and is of major public health importance. Most of the top therapeutic areas for patient savings programs are for chronic conditions where patient adherence to their healthcare professional s recommended therapy is important and conditions are often asymptomatic. The top therapeutic areas include many treatment options, including both generic and branded medicines. Across the top 10 therapeutic areas for Patient Savings Programs, the number of prescriptions filled ranged from 9.2 million to 1.1 million, and the share of prescriptions filled under these programs ranged from 1% to 9% of total prescriptions for that class. EXHIBIT 3 Top Therapeutic Areas for Patient Savings Programs Top 10 Therapeutic Areas by number of prescriptions using PSP Programs Rx Share by Branded PSP, Generic PSP and non PSP scripts Top 10 PSP Therapeutic Areas PSP Rx Counts (in Millions) PSP Patient Counts (in Millions) No. of Programs CHOLESTEROL 7% 93% CHOLESTEROL GERD 9% 91% GERD CONTRACEPTIVE ADHD HYPERTENSION 5% 6% 1% 95% 94% 99% CONTRACEPTIVE ADHD ASTHMA 3% 97% HYPERTENSION DIABETES ALLERGIES PAIN 2% 6% 1% 98% 94% 99% ASTHMA DIABETES SLEEP DISORDER 2% 98% ALLERGIES % 20% 40% 60% 80% 100% PAIN Branded PSP Scripts Scripts without PSP SLEEP DISORDER

6 Level of initial co-pays (see Exhibit 4) Of the 1.2% of total prescriptions filled using Prescription Savings Programs, 93% were for products with an initial co-pay of more than $20, including 34% that were prescriptions with co-pays in excess of $50. The share of prescriptions filled under a Patient Savings Program in each therapy area with co-pays in excess of $50 range from 14% in the case of allergies to 48% in the pain therapy area. A wide range of initial co-pays are observed for prescriptions filled using Prescription Savings Programs, with initial co-pays ranging as high as several hundred dollars. In the case of diabetes treatments, for example, 13% of prescriptions filled had an initial copay of $100 or more, including 5% with initial co-pays in excess of $200 per prescription. EXHIBIT 4 Level of Initial Co-Pays PSP Usage by Therapeutic Area and Initial Co-Pay (Top 10 by Number of Total Rx s Supported by Programs) ALL MARKETS 7% 59% 34% CHOLESTEROL 7% 68% 26% GERD 2% 57% 41% CONTRACEPTIVE 6% 60% 34% ADHD 6% 59% 35% HYPERTENSION 2% 59% 39% ASTHMA 12% 61% 27% DIABETES 10% 57% 32% ALLERGIES 16% 70% 14% PAIN 4% 48% 48% SLEEP DISORDER 5% 52% 43% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% $0 - $20 (Rx: 3.2M) $20.01 to $50 (Rx: 25.3M) $ (Rx: 14.6M) 6

7 Patient Savings and Out-of-Pocket Costs (see Exhibit 5) The average patient savings per prescription filled under a Patient Savings Program was $40, and ranged from $24 on average per contraceptive prescription filled under a Patient Savings Program to $46 per ADHD prescription. The range of savings per prescription is wide: for example, the average savings per diabetes prescription is $42 but over 10% of prescriptions saved the patient in excess of $100. Patients using Patient Savings Programs were left with an average final out of pocket cost of $26 per prescription. EXHIBIT 5 Patient Savings and Final Out of Pocket Costs Average Patient Savings per Rx Using PSPs ALL MARKETS CHOLESTEROL GERD CONTRACEPTIVE ADHD HYPERTENSION ASTHMA DIABETES ALLERGIES ALLERGIES PAIN PAIN SLEEP DISORDER SLEEP DISORDER $40 $34 $43 $24 $46 $46 $32 $30 $42 $42 $28 $28 $35 $35 $37 $ CONTRACEPTIVE SLEEP DISORDER Average Patient Out of Pocket Costs per Rx after PSP Program ALL MARKETS CHOLESTEROL GERD ADHD HYPERTENSION ASTHMA DIABETES ALLERGIES PAIN $21 $24 $24 $25 $25 $24 $26 $26 $25 $28 $ Average Patient Savings Average Final Patient Out Of Pocket Costs 7

8 PROGRAM LENGTH IN MONTHS Longevity of Patient Savings Programs (see Exhibit 6) Almost all Patient Savings Programs continue to run for many years. Only three programs that were launched prior to 2009 had been terminated by the end of October 2012 Of the 296 existing brands with Patient Savings Program programs launched prior to 2009, 80% had programs running for more than two years as of the end of October EXHIBIT 6 Longevity of Patient Savings Programs Number of Brands by Length of Days (Excluding Products Launched 2009+) 43 to 45 Months 40 to 42 Months 37 to 39 Months 34 to 36 Months 31 to 33 Months 28 to 30 Months 25 to 27 Months 22 to 24 Months 19 to 21 Months 16 to 18 Months 13 to 15 Months 10 to 12 Months 7 to 9 Months 4 to 6 Months 1 to 3 Months Only three of these brands ended all programs during study period Count of Brands Note: Search for start date ended on January 2009 which results in the majority of programs starting this month Brands launched from 2009 and after are not included in the length of program analysis above Results include data for third party payers only 8

9 Use of branded patient savings programs when generic products are available (see Exhibit 7) Of the 526 Patient Savings Programs for branded drugs, 459 programs are for brands which do not have an AB equivalent 3 generic product also available in the market. The 67 branded programs where AB equivalent generic products are available accounted for 0.05% of the total number of prescriptions filled during the 12 months period analyzed. EXHIBIT 7 Use of Branded Patient Savings Programs when Generic Products are Available 526 Branded Programs with or without AB Equivalents (Molecular Level) Percent of Total Prescriptions where Brands are competing with AB Equivalent at Molecule Level: 0.05% Branded Programs Do not compete with AB Equivalent Compete with AB Equivalent Study Limitations This analysis is based on IMS Health anonymized patient longitudinal prescription data as reported by retail pharmacies and captured in the IMS Health National Prescription Audit. As a result, Patient Savings Programs that operate through mail order or other non-retail pharmacies are not covered, including certain orphan, specialty and oncology product programs. In addition, the Patient Savings Programs analyzed in this report are limited to those having 100 or more unique patients assisted during the 12 month period ending October 31, While Patient Savings Programs are only utilized to offset the patient costs for prescriptions purchases entirely by the patient (i.e. cash purchases) or in part by third party commercial payers, this analysis only considers prescriptions filled under third party commercial payer plans. 3 AB equivalent drugs are products meeting necessary bioequivalence requirements as specified by the Food and Drug Administration 9

10 Co-insurance payments and insurance deductibles are not included in calculations of patient total out of pocket costs; only deductibles paid at the point of prescription dispensing are included and the impact of Patient Savings Programs on those amounts. Discussion Patient Savings Programs have been introduced in part to provide support for patients who may otherwise be deterred from treatment options due to high out-of-pocket costs associated with their use. These programs are for medicines covering a broad range of important therapy classes associated with diseases affecting large patient populations. This study is intended to describe the magnitude, extent and impact of Patient Savings Program currently available in the U.S. market. While prescriptions filled using Patient Savings Programs represent only 1.2% of total scripts and 6.1% of branded scripts, over 14 million patients received some benefit over the course of a twelve month period from lower out of pocket copay costs provided by these programs across a broad range of therapy areas. This reflects the finding that while these programs cover a large part of the market, their overall level of use is modest relative to the total medicines market. The average co-pay for a patient after applying the Patient Savings Program savings was $26, providing an average savings per prescription of $40. The range of savings varies considerably and patient savings in some cases exceed $100 or more per prescription. The study also finds that the vast majority of programs are for branded medicines for which no AB equivalent generic product is available. Patient Savings Programs run for long time spans, providing continuous support to eligible patients who are able to anticipate ongoing assistance with co-pay levels over many years. Overall, this study suggests that Patient Savings Programs play a selective and meaningful role in addressing patient concerns about co-pay levels and out of pockets costs, enabling them to receive the benefits from medicines prescribed by their healthcare professional. Further study is required to assess the impact of these programs on patient health outcomes and utilization of health services. 10

11 About the Institute The IMS Institute for Healthcare Informatics leverages collaborative relationships in the public and private sectors to strengthen the vital role of information in advancing healthcare globally. Its mission is to provide key policy setters and decision makers in the global health sector with unique and transformational insights into healthcare dynamics derived from granular analysis of information. Fulfilling an essential need within healthcare, the Institute delivers objective, relevant insights and research that accelerate understanding and innovation critical to sound decision making and improved patient care. With access to IMS Health s extensive global data assets and analytics, the Institute works in tandem with a broad set of healthcare stakeholders, including government agencies, academic institutions, the life sciences industry and payers, to drive a research agenda dedicated to addressing today s healthcare challenges. By collaborating on research of common interest, it builds on a long-standing and extensive tradition of using IMS Health information and expertise to support the advancement of evidence-based healthcare around the world. Research Agenda The research agenda for the Institute centers on five areas considered vital to the advancement of healthcare globally: The effective use of information by healthcare stakeholders globally to improve health outcomes, reduce costs and increase access to available treatments. Optimizing the performance of medical care through better understanding of disease causes, treatment consequences and measures to improve quality and cost of healthcare delivered to patients. Understanding the future global role for biopharmaceuticals, the dynamics that shape the market and implications for manufacturers, public and private payers, providers, patients, pharmacists and distributors. Researching the role of innovation in health system products, processes and delivery systems, and the business and policy systems that drive innovation. Informing and advancing the healthcare agendas in developing nations through information and analysis. Guiding Principles The Institute operates from a set of guiding principles: The advancement of healthcare globally is a vital, continuous process. Timely, high-quality and relevant information is critical to sound healthcare decision making. Insights gained from information and analysis should be made widely available to healthcare stakeholders. 11

12 Effective use of information is often complex, requiring unique knowledge and expertise. The ongoing innovation and reform in all aspects of healthcare require a dynamic approach to understanding the entire healthcare system. Personal health information is confidential and patient privacy must be protected. The private sector has a valuable role to play in collaborating with the public sector related to the use of healthcare data. 12

Comparison of Hepatitis C Treatment Costs

Comparison of Hepatitis C Treatment Costs September 2016 Comparison of Hepatitis C Treatment Costs Estimates of Net Prices and Usage in the U.S. and Other Major Markets $ Introduction A new generation of Hepatitis C treatments has generated significant

More information

PRESCRIPTION MEDICINES: COSTS IN CONTEXT

PRESCRIPTION MEDICINES: COSTS IN CONTEXT PRESCRIPTION MEDICINES: COSTS IN CONTEXT 2015 Since 2000, biopharmaceutical companies have brought MORE THAN 500 NEW TREATMENTS AND CURES to U.S. patients In the last 100 years, medicines have helped raise

More information

Contents General Information... 1. General Information

Contents General Information... 1. General Information Contents General Information... 1 Preferred Drug List... 2 Pharmacies... 3 Prescriptions... 4 Generic and Preferred Drugs... 5 Express Scripts Website and Mobile App... 5 Specialty Medicines... 5 Prior

More information

Drug Pricing, Repricing, Rebates, and Patient Access

Drug Pricing, Repricing, Rebates, and Patient Access Drug Pricing, Repricing, Rebates, and Patient Access Jack Hoadley, Ph.D. Health Policy Institute, Georgetown University Bipartisan Policy Center April 13, 2016 1 Credits and Notes Some of my drug policy

More information

Specialty Pharmacy Market Landscape. Developed by:

Specialty Pharmacy Market Landscape. Developed by: Specialty Pharmacy Market Landscape Developed by: 2016 AGENDA TOPIC Specialty Pharmacy Overview Specialty Drug Trend Utilization Specialty Pharmacy Provider Profiles and Services Specialty Pharmacy Provider

More information

Understanding your Blue Cross prescription drug plan

Understanding your Blue Cross prescription drug plan Understanding your Blue Cross prescription drug plan Blue Cross Blue Shield of Michigan gives you comprehensive coverage for your medications. Your prescription drug plan includes Blue Cross support and

More information

CompPharma. Manage. Process. Inform. Ensure. The Role of a PBM in Workers Compensation

CompPharma. Manage. Process. Inform. Ensure. The Role of a PBM in Workers Compensation Manage Inform Process Ensure The Role of a PBM in Workers Compensation Understanding the role of workers compensation pharmacy benefit managers (WC-PBMs) can help state and local government agencies ensure

More information

Impact of Health Reform on Prescription Drugs

Impact of Health Reform on Prescription Drugs Impact of Health Reform on Prescription Drugs 1 Indirect Effects Increased Rx Volume = More Prescriptions! Page 2 Retiree Drug Subsidy (RDS) Before HCR Tax-Free Subsidy RDS as taxdeductible income After

More information

Specialty Pharmacy Market Landscape. Developed by:

Specialty Pharmacy Market Landscape. Developed by: Specialty Pharmacy Market Landscape Developed by: 2016 AGENDA TOPIC Specialty Pharmacy Overview Specialty Drug Trend Utilization Specialty Pharmacy Provider Profiles and Services Specialty Pharmacy Provider

More information

GENERAL INFORMATION. With Express Scripts, you have access to:

GENERAL INFORMATION. With Express Scripts, you have access to: CONTENTS GENERAL INFORMATION... 1 PREFERRED DRUG LIST....2 PHARMACIES... 3 PRESCRIPTIONS... 4 GENERIC AND PREFERRED DRUGS... 5 EXPRESS SCRIPTS WEBSITE AND MOBILE APP... 5 SPECIALTY MEDICATIONS... 6 PRIOR

More information

An Evidence-based Approach to Understanding the Benefits of Co-pay Reduction

An Evidence-based Approach to Understanding the Benefits of Co-pay Reduction JUNE 30, 2015 An Evidence-based Approach to Understanding the Benefits of Co-pay Reduction From the PSKW Reports White Paper Series Table of Contents Introduction... 2 1. Poor Medication Adherence Increases

More information

Below are some frequently asked questions that will provide you with valuable information.

Below are some frequently asked questions that will provide you with valuable information. Welcome to your prescription drug benefit administered by CVS Caremark. Your prescription benefit is designed to bring you quality pharmacy care that will help you save money. Below are some frequently

More information

e -Prescribing An Information Brief

e -Prescribing An Information Brief e -Prescribing An Information Brief Prepared by: Maryland Health Care Commission June 2008 Introduction Technology creates efficiencies and opportunities in almost every industry, and health care is no

More information

Prescription drug costs continue to rise at

Prescription drug costs continue to rise at Prescription Drugs Developing an Effective Generic Prescription Drug Program by John D. Jones Pharmacy benefit managers (PBMs) use a variety of pricing strategies. When employers have a thorough knowledge

More information

Medication Therapy Management (MTM) Program

Medication Therapy Management (MTM) Program Medication Therapy Management (MTM) Program Regence offers a Medication Therapy Management (MTM) program to ensure you are receiving the most effective medications, while also helping to reduce the risk

More information

2016 Group Retiree Medicare Plans

2016 Group Retiree Medicare Plans 2016 Group Retiree Medicare Plans Blue Cross MedicareRx (PDP) Medicare Part D Prescription Drug Plans Anthem Blue Cross is a stand-alone prescription drug plan with a Medicare contract. Enrollment in Anthem

More information

2014 Prescription Drug Schedule Humana Medicare Employer Plan

2014 Prescription Drug Schedule Humana Medicare Employer Plan 2014 Prescription Drug Schedule Humana Medicare Employer Plan Option 98 City of Newport News Y0040_GHHHEF3HH14 SECTION I - INTRODUCTION TO SUMMARY OF BENEFITS Thank you for your interest in the Humana

More information

April 28, 2014. Submitted electronically via www.regulations.gov

April 28, 2014. Submitted electronically via www.regulations.gov April 28, 2014 Department of Health and Human Services Office of the National Coordinator for Health Information Technology Attention: 2015 Edition EHR Standards and Certification Criteria Proposed Rule

More information

Brought to you by the insurance professionals at Rosenfeld Einstein, A Marsh & McLennan Agency, LLC Company

Brought to you by the insurance professionals at Rosenfeld Einstein, A Marsh & McLennan Agency, LLC Company Brought to you by the insurance professionals at Rosenfeld Einstein, A Marsh & McLennan Agency, LLC Company Prescription Drug Trends As prescription drug costs continue to increase, it is important for

More information

c. determine the factors that will facilitate/limit physician utilization of pharmacists for medication management services.

c. determine the factors that will facilitate/limit physician utilization of pharmacists for medication management services. Consumer, Physician, and Payer Perspectives on Primary Care Medication Management Services with a Shared Resource Pharmacists Network Marie Smith, PharmD and Michlle Breland, PhD University of Connecticut,

More information

Pharmacy Benefit Programs

Pharmacy Benefit Programs Pharmacy Benefit Programs Reducing costs and supporting better health Our pharmacy benefit programs range from those based on the U.S. Food and Drug Administration (FDA) guidelines to innovative initiatives.

More information

About NEHI: NEHI is a national health policy institute focused on enabling innovation to improve health care quality and lower health care costs.

About NEHI: NEHI is a national health policy institute focused on enabling innovation to improve health care quality and lower health care costs. 1 Aaron McKethan PhD (amckethan@rxante.com) About NEHI: NEHI is a national health policy institute focused on enabling innovation to improve health care quality and lower health care costs. In partnership

More information

Prescription Drug Plan

Prescription Drug Plan Prescription Drug Plan The prescription drug plan helps you pay for prescribed medications using either a retail pharmacy or the mail order program. For More Information Administrative details and procedures

More information

MESSA Saver Rx PRESCRIPTION DRUG RIDER BOOKLET. Good Health. Good Business. Great Schools.

MESSA Saver Rx PRESCRIPTION DRUG RIDER BOOKLET. Good Health. Good Business. Great Schools. MESSA Saver Rx PRESCRIPTION DRUG RIDER BOOKLET Good Health. Good Business. Great Schools. MESSA Saver Rx Prescription Drug Program The MESSA Saver Rx Prescription Drug Program is made available by a Group

More information

SUPER SPENDING. U.S. TRENDS in HIGH-COST MEDICATION USE AN EXPRESS SCRIPTS REPORT MAY 2015

SUPER SPENDING. U.S. TRENDS in HIGH-COST MEDICATION USE AN EXPRESS SCRIPTS REPORT MAY 2015 SUPER SPENDING U.S. TRENDS in HIGH-COST MEDICATION USE AN EXPRESS SCRIPTS REPORT MAY 2015 A Note from Glen Stettin, MD Senior Vice President, Clinical, Research & New Solutions Improving Care for the Costliest

More information

Remove Access Barriers and Maximize Product Uptake with an Integrated Hub Model Approach

Remove Access Barriers and Maximize Product Uptake with an Integrated Hub Model Approach Remove Access Barriers and Maximize Product Uptake with an Integrated Hub Model Approach When it comes to supporting the clinical and marketing objectives of any pharmaceutical franchise, helping to remove

More information

FREQUENTLY ASKED QUESTIONS ABOUT THE CVS CAREMARK PRESCRIPTION DRUG PROGRAM

FREQUENTLY ASKED QUESTIONS ABOUT THE CVS CAREMARK PRESCRIPTION DRUG PROGRAM FREQUENTLY ASKED QUESTIONS ABOUT THE CVS CAREMARK PRESCRIPTION DRUG PROGRAM ABBVIE EMPLOYEES WANT TO KNOW What s New in 2015? AbbVie is making changes in its pharmacy benefit program to ensure our medical

More information

RMIP Prescription Plan FAQ's

RMIP Prescription Plan FAQ's RMIP Prescription Plan FAQ's A new U.S. Pharmacy Benefit Manager has been selected for January 1, 2015 - CVS/caremark. 1) Why is the RMIP changing to CVS/caremark? The Express Scripts contract ends on

More information

About the Program 1. What is the current Osphena (ospemifene) Savings Offer for 30 day prescription?

About the Program 1. What is the current Osphena (ospemifene) Savings Offer for 30 day prescription? 2015 Osphena Savings Program Frequently Asked Questions Click here for Full Prescribing Information, including Boxed WARNING regarding Endometrial Cancer and Cardiovascular Disorders. Have a question about

More information

University of Nebraska Prescription Drug Program 2014

University of Nebraska Prescription Drug Program 2014 University of Nebraska Prescription Drug Program 2014 The University of Nebraska s prescription benefit program is administered by CVS Caremark, a leading national provider of prescription drug benefit

More information

For a Healthier America: Reducing Prescription Drug Misuse and Abuse

For a Healthier America: Reducing Prescription Drug Misuse and Abuse For a Healthier America: Reducing Prescription Drug Misuse and Abuse The misuse and abuse of prescription medicines is a growing public health problem. In addition to the tragic toll on families and communities,

More information

Pfizer Struggles to Maintain Lipitor Sales Will Aggressive Discounting and Rebating Pay Off?

Pfizer Struggles to Maintain Lipitor Sales Will Aggressive Discounting and Rebating Pay Off? Pfizer Struggles to Maintain Lipitor Sales Will Aggressive Discounting and Rebating Pay Off? Research February 6, 2012 Rusty Jones Companies: Pfizer (PFE) Ranbaxy (OTC: RBXZF) Watson (WPI) Products: Lipitor

More information

Medicare Part D Prescription Drug Coverage

Medicare Part D Prescription Drug Coverage Medicare Part D Prescription Drug Coverage Part 3 Version 7.1 August 1, 2013 Terms and Conditions This training program is protected under United States Copyright laws, 17 U.S.C.A. 101, et seq. and international

More information

Annual Notice of Changes for 2015

Annual Notice of Changes for 2015 Express Scripts Medicare (PDP) for Consolidated Associations of Railroad Employees (CARE) Annual Notice of Changes for 2015 You are currently enrolled as a member of Express Scripts Medicare (PDP). The

More information

Available to Those who ARE Medicare Eligible

Available to Those who ARE Medicare Eligible LACERA is proud to offer comprehensive medical plans to Los Angeles County retirees and their eligible dependents. Eligibility for some plans depends on whether the person being insured is eligible for

More information

Medicare Part D Prescription Drug Coverage

Medicare Part D Prescription Drug Coverage Medicare Part D Prescription Drug Coverage Part 3 Version 9.0 June 22, 2015 Terms and Conditions This training program is protected under United States Copyright laws, 17 U.S.C.A. 101, et seq. and international

More information

Introduction. Plan sponsors include employers, unions, trust funds, associations and government agencies, and are also referred to as payors.

Introduction. Plan sponsors include employers, unions, trust funds, associations and government agencies, and are also referred to as payors. Maintaining the Affordability of the Prescription Drug Benefit: How Managed Care Organizations Secure Price Concessions from Pharmaceutical Manufacturers Introduction The purpose of this paper is to explain

More information

Agenda. Medicare Overview Medicare Part B Drug Coverage Medicare Part D: How to Find and Compare Medicare Part D Plans Summary Provider Contacts

Agenda. Medicare Overview Medicare Part B Drug Coverage Medicare Part D: How to Find and Compare Medicare Part D Plans Summary Provider Contacts 2 Medicare Part D Agenda Medicare Overview Medicare Part B Drug Coverage Medicare Part D: Background Benefits of Medicare Part D Enrollment Coverage Specialty Medications Part D Costs How to Find and Compare

More information

Princeton University Prescription Drug Plan Summary Plan Description

Princeton University Prescription Drug Plan Summary Plan Description Princeton University Prescription Drug Plan Summary Plan Description Princeton University Prescription Drug Plan Summary Plan Description January 2015 Contents Introduction... 1 How the Plan Works... 2

More information

UNDERSTANDING YOUR HEALTH NET PHARMACY BENEFITS Los Angeles Unified School District Learning about your pharmacy benefits can save you time and money

UNDERSTANDING YOUR HEALTH NET PHARMACY BENEFITS Los Angeles Unified School District Learning about your pharmacy benefits can save you time and money UNDERSTANDING YOUR HEALTH NET PHARMACY BENEFITS Los Angeles Unified School District Learning about your pharmacy benefits can save you time and money HEALTH NET MAKES USING YOUR NEW PHARMACY PLAN TROUBLE-FREE

More information

Most countries will experience an increase in pharmaceutical spending per capita by 2018

Most countries will experience an increase in pharmaceutical spending per capita by 2018 6 Most countries will experience an increase in pharmaceutical spending per capita by 218 Pharmaceutical spending per capita, 213 versus 218 1,6 1,4 Pharmaceutical Spend per Capita 1,2 1, 8 6 4 2 US Japan

More information

Pharmacy Benefit Managers: What we do

Pharmacy Benefit Managers: What we do Pharmacy Benefit Managers: What we do Steve Boekenoogen, Pharm.D. Poulsbo, WA & San Diego CA Manager, Clinical Services & Integration MedImpact Healthcare Systems, Inc Dan Danielson, M.S., RPh. Lynnwood,

More information

The Facts, Figures and Trends in U.S. Pharmaceutical Distribution Gayle C. Johnston, President, CuraScript SD Miguel Rodriguez, Senior Product

The Facts, Figures and Trends in U.S. Pharmaceutical Distribution Gayle C. Johnston, President, CuraScript SD Miguel Rodriguez, Senior Product The Facts, Figures and Trends in U.S. Pharmaceutical Distribution Gayle C. Johnston, President, CuraScript SD Miguel Rodriguez, Senior Product Manager, CuraScript SD 2015 Distribution Management Conference

More information

Annual Notice of Changes for 2014

Annual Notice of Changes for 2014 Advocare Spirit Rx (HMO-POS) offered by Security Health Plan of Wisconsin, Inc. Annual Notice of Changes for 2014 You are currently enrolled as a member of Advocare Spirit Rx (HMO-POS). Next year there

More information

The Evolving Dynamics of Specialty Pharmacy in Oncology

The Evolving Dynamics of Specialty Pharmacy in Oncology February 2013 Edition Vol. 7, Issue 2 The Evolving Dynamics of Specialty Pharmacy in Oncology By: Deni Deasy Boekell, Senior Director, Commercial Planning, Kantar Health With the increasing use of specialty

More information

Formulary Management

Formulary Management Formulary Management Formulary management is an integrated patient care process which enables physicians, pharmacists and other health care professionals to work together to promote clinically sound, cost-effective

More information

January 2016. Price Declines after Branded Medicines Lose Exclusivity in the U.S.

January 2016. Price Declines after Branded Medicines Lose Exclusivity in the U.S. January 2016 Price Declines after Branded Medicines Lose Exclusivity in the U.S. Introduction When novel medicines lose exclusivity in the United States, competitors quickly enter the market and bring

More information

Introducing... Active Pharmacy service SM. Innovative new ways to enhance benefits and reduce costs

Introducing... Active Pharmacy service SM. Innovative new ways to enhance benefits and reduce costs Introducing... Active Pharmacy service SM Innovative new ways to enhance benefits and reduce costs Did you know... that healthcare costs in Canada have doubled in the last decade?* Added value and cost

More information

Customized Patient Care through Patient Support Programs for Rare/Orphan Drugs. Sandra Anderson August 2015

Customized Patient Care through Patient Support Programs for Rare/Orphan Drugs. Sandra Anderson August 2015 Customized Patient Care through Patient Support Programs for Rare/Orphan Drugs Sandra Anderson August 2015 Why Orphan Drugs are Different Difficult to diagnose Population size Unique patient and caregiver

More information

Summary Table of Benefits Select Medicare Supplement Plan

Summary Table of Benefits Select Medicare Supplement Plan 2016 EXCLUSIVE CARE SUMMARY OF COVERED BENEFITS Select Medicare Eligible Supplement Plan Summary Table of Benefits Select Medicare Supplement Plan PLAN REIMBURSEMENT METHOD DEDUCTIBLE - Individual Medicare

More information

Chapter 2 Standards for EHRs 1 Chapter 2 Content: LO 2.1 Describe EHR Standards History LO 2.2 Identify basic HIPAA regulations LO 2.3 List basic CHI regulations LO 2.4 Summarize IOM s Core Functions LO

More information

The Evolving Landscape of Payment Care Delivery and Manufacturer Implications of Coverage Expansion

The Evolving Landscape of Payment Care Delivery and Manufacturer Implications of Coverage Expansion November 2013 Edition Vol. 7, Issue 10 The Evolving Landscape of Payment Care Delivery and Manufacturer Implications of Coverage Expansion By Gordon Gochenauer, Director, Oncology Commercial Strategies,

More information

Tips, Tricks and Traps Practical Insights into 340B

Tips, Tricks and Traps Practical Insights into 340B Tips, Tricks and Traps Practical Insights into 340B Assessing the Opportunity in Ambulatory and Specialty Pharmacy Kevin Scheckelhoff, RPh, MBA Asst. Vice President 340B Solutions, McKesson Chris Shain,

More information

Petitioner, Respondents.

Petitioner, Respondents. No. 12-416 IN THE Supreme Court of the United States FEDERAL TRADE COMMISSION, Petitioner, v. WATSON PHARMACEUTICALS, INC., et al., Respondents. ON WRIT OF CERTIORARI TO THE UNITED STATES COURT OF APPEALS

More information

Arthritis Foundation Position Statement on Biosimilar Substitution

Arthritis Foundation Position Statement on Biosimilar Substitution Arthritis Foundation Position Statement on Biosimilar Substitution The Affordable Care Act creates a regulatory pathway for the approval of a new generation of biologic medications called biosimilars.

More information

Prescription Plan FAQ s

Prescription Plan FAQ s Prescription Plan FAQ s What is a specialty medication? Specialty medication is the term used to describe certain medications and a set of services designed to meet the particular needs of people who take

More information

DC DEPARTMENT OF HEALTH Pharmaceutical Procurement and Distribution Pharmaceutical Warehouse. DC Health Care Safety Net ALLIANCE PROGRAM

DC DEPARTMENT OF HEALTH Pharmaceutical Procurement and Distribution Pharmaceutical Warehouse. DC Health Care Safety Net ALLIANCE PROGRAM DC DEPARTMENT OF HEALTH Pharmaceutical Warehouse DC Health Care Safety Net ALLIANCE PROGRAM OPERATIONAL PROTOCOLS Operational protocols for the DC Health Care Alliance program through the DOH Pharmaceutical

More information

December 2014. Federal Employees Health Benefits (FEHB) Program Report on Health Information Technology (HIT) and Transparency

December 2014. Federal Employees Health Benefits (FEHB) Program Report on Health Information Technology (HIT) and Transparency December 2014 Federal Employees Health Benefits (FEHB) Program Report on Health Information Technology (HIT) and Transparency I. Background Federal Employees Health Benefits (FEHB) Program Report on Health

More information

White Paper: Formulary Development at Express Scripts

White Paper: Formulary Development at Express Scripts White Paper: Formulary Development at Express Scripts Express Scripts works with health-benefit plan sponsors and individual members of health plans to provide affordable access to clinically sound, high-quality

More information

Frequently Asked Questions: Medicare Supplement & Medicare Advantage

Frequently Asked Questions: Medicare Supplement & Medicare Advantage Frequently Asked Questions: Medicare Supplement & Medicare Advantage Who is eligible for CBIA s Medicare program? A CBIA Health Connections participant is eligible for either plan if they are qualified

More information

Your Retiree Health Care Travel Guide

Your Retiree Health Care Travel Guide SPECIAL EDITION for Individuals Not Yet Eligible for Medicare Your Retiree Health Care Travel Guide 2010 Enrollment for BorgWarner Pre-Medicare Health Care Coverage Welcome to 2010 Pre-Medicare enrollment!

More information

ExchangE PulsE PUBLIC EXCHANGES REPORT APRIL 2014

ExchangE PulsE PUBLIC EXCHANGES REPORT APRIL 2014 Exchange Pulse PUBLIC EXCHAGES REPORT April 2014 executive summary Public Exchange Medication Utilization: Preliminary Insights and The public health insurance exchanges afford substantial financial opportunities

More information

Welcome to. Prompt Fulfillment and Delivery 1-844-CUBIST-CARES (1-844-282-4782)

Welcome to. Prompt Fulfillment and Delivery 1-844-CUBIST-CARES (1-844-282-4782) Welcome to When you prescribe SIVEXTRO (tedizolid phosphate) to your patients, our goal is to ensure they have access. That is why AccessSIVEXTRO is committed to helping eligible patients so they can receive

More information

Payer Mix in Oncology

Payer Mix in Oncology Emerging Markets Market Access & Health Outcomes Oncology Payer Mix in Oncology Understanding cancer payer mix is critical to understanding patient affordability as a component of launch planning Digital

More information

THE GROWTH IN SPECIALTY DRUG SPENDING FROM 2013 TO 2014

THE GROWTH IN SPECIALTY DRUG SPENDING FROM 2013 TO 2014 THE GROWTH IN SPECIALTY DRUG SPENDING FROM 2013 TO 2014 This report was written by HealthCore, a wholly-owned and independently operated health outcomes subsidiary of Anthem, Inc. The Growth in Specialty

More information

A reliable and convenient way to optimize your prescription drug benefit

A reliable and convenient way to optimize your prescription drug benefit Introducing... Pharmacy Benefit Management and the Express Scripts Canada Pharmacy SM A reliable and convenient way to optimize your prescription drug benefit Did you know... that healthcare costs in Canada

More information

Novel Opportunities for Engagement Utilizing in House Pharmacy Services

Novel Opportunities for Engagement Utilizing in House Pharmacy Services Novel Opportunities for Engagement Utilizing in House Pharmacy Services Ray Bailey, BSPharm RPh Director of Pharmacy, FCS Rx to Go Pharmacy rbailey@flcancer.com Angel Aslo, Pharm.D. Director of Pharmacy,

More information

Nova Scotia Pharmacare Programs

Nova Scotia Pharmacare Programs Nova Scotia Pharmacare Programs The Nova Scotia Family Pharmacare Program Effective December 2012 The information in this booklet is subject to change and does not replace the Health Services and Insurance

More information

Strategic Issues in Managing the Specialty Pharmacy Benefit. Tim Watson, PharmD, MBA

Strategic Issues in Managing the Specialty Pharmacy Benefit. Tim Watson, PharmD, MBA Strategic Issues in Managing the Specialty Pharmacy Benefit Tim Watson, PharmD, MBA Strategic Issues in Specialty Pharmacy Management Specialty pharmacy goals: Provide a reliable source for hard-to-find

More information

Introduction to Medication Management Systems, Inc. Comprehensive Medication Therapy Management Solutions

Introduction to Medication Management Systems, Inc. Comprehensive Medication Therapy Management Solutions Introduction to Medication Management Systems, Inc. Comprehensive Medication Therapy Management Solutions Vision Medication Management Systems, Inc. (MMS) envisions a health care system in which all patients

More information

GENERIC DRUG SAVINGS IN THE U.S. SEVENTH ANNUAL EDITION: 2015

GENERIC DRUG SAVINGS IN THE U.S. SEVENTH ANNUAL EDITION: 2015 GENERIC DRUG SAVINGS IN THE U.S. SEVENTH ANNUAL EDITION: 2015 Rising health care costs continue to be a major concern for everyone from patients to policymakers. But there is some good news. Savings from

More information

Practice Advisory on Collaborative Drug Therapy Management

Practice Advisory on Collaborative Drug Therapy Management I. Introduction Practice Advisory on Collaborative Drug Therapy Management Collaborative drug therapy management (CDTM) is a formal partnership between a pharmacist and physician or group of pharmacists

More information

The Honorable Alphonso Maldon, Jr. Chairman Military Compensation and Retirement Modernization Commission P. O. Box 13170 Arlington, Virginia 22209

The Honorable Alphonso Maldon, Jr. Chairman Military Compensation and Retirement Modernization Commission P. O. Box 13170 Arlington, Virginia 22209 The Honorable Alphonso Maldon, Jr. Chairman Military Compensation and Retirement Modernization Commission P. O. Box 13170 Arlington, Virginia 22209 Dear Chairman Maldon: The National Association of Chain

More information

www.oxfordhealth.com

www.oxfordhealth.com www.oxfordhealth.com Oxford s HMO products are underwritten by Oxford Health Plans (NY), Inc., Oxford Health Plans (NJ), Inc., and Oxford Health Plans (CT), Inc., and insurance products are underwritten

More information

Welcome to the LILETTA Patient Savings Program

Welcome to the LILETTA Patient Savings Program Welcome to the LILETTA Patient Savings Program Eligible insured patients, activate your card today* * See full program Terms and Conditions on page 3 of this brochure or at LILETTAcard.com. Help With Your

More information

Based on the work of Senior PharmAssist in Durham, North Carolina

Based on the work of Senior PharmAssist in Durham, North Carolina A Guide for Implementing a Community-based Pharmaceutical Assistance Program Supporting healthier living for older adults through user-friendly access to appropriate medications, health education, community

More information

PRESCRIPTION DRUG PLAN

PRESCRIPTION DRUG PLAN PRESCRIPTION DRUG PLAN The Plan Administrator will pay a portion of the cost of covered prescriptions. Maximum benefits are paid when prescriptions are filled through the CVS Caremark network pharmacies.

More information

Pharmacy Handbook. Understanding Your Prescription Benefit

Pharmacy Handbook. Understanding Your Prescription Benefit Pharmacy Handbook Understanding Your Prescription Benefit 1 Welcome to Your Prescription Drug Plan! Health Republic Insurance of New York has partnered with US Script to manage your prescription drug benefits.

More information

Prescription Drug Program Summary

Prescription Drug Program Summary Prescription Drug Program Summary Express Scripts is one of the most experienced full-service pharmacy benefit management firms (PBM) in the nation. Express Scripts contracts with pharmaceutical manufacturing

More information

Submitted electronically to http://www.regulations.gov

Submitted electronically to http://www.regulations.gov Submitted electronically to http://www.regulations.gov Centers for Medicare and Medicaid Services Department of Health and Human Services Attention: CMS-3288-NC P.O. Box 8016 Baltimore, MD 21244-8016 RE:

More information

Prescription Drugs Medicare- Eligible Participants

Prescription Drugs Medicare- Eligible Participants State Retiree Health Benefits Program Fact Sheet #8A Prescription Drugs Medicare- Eligible Participants As a Medicare-eligible participant in the State Retiree Health Benefits Program, what are my choices

More information

Roadmap for Medicare Navigating Medicare Part D. A guide for seniors and caregivers

Roadmap for Medicare Navigating Medicare Part D. A guide for seniors and caregivers Roadmap for Medicare Navigating Medicare Part D A guide for seniors and caregivers Roadmap for Medicare: Getting Oriented This Guide offers information and advice for choosing a Medicare Part D prescription

More information

PHARMACY BENEFIT DESIGN CONSIDERATIONS

PHARMACY BENEFIT DESIGN CONSIDERATIONS PHARMACY BENEFIT DESIGN CONSIDERATIONS Is your pharmacy benefit designed for your employees or the big drug companies? The pharmacy (or prescription) benefit is one of the most sought after benefits by

More information

ACTIVELY MANAGED DRUG SOLUTIONS. for maintenance and specialty medication. Actively Managed Drug Solutions is not available in the province of Quebec

ACTIVELY MANAGED DRUG SOLUTIONS. for maintenance and specialty medication. Actively Managed Drug Solutions is not available in the province of Quebec ACTIVELY MANAGED DRUG SOLUTIONS for maintenance and specialty medication Actively Managed Drug Solutions is not available in the province of Quebec ARE YOU UNDERESTIMATING THE IMPACT OF CHRONIC DISEASE?

More information

CLOSING THE COVERAGE GAP. Pan-Canadian Pharmacare

CLOSING THE COVERAGE GAP. Pan-Canadian Pharmacare CLOSING THE COVERAGE GAP Pan-Canadian Pharmacare Prescription drug coverage for all Canadians While the vast majority of Canadians have access to prescription drugs, some Canadians can t afford their medications.

More information

There are doctors who specialize in medical conditions. Now there are pharmacists who specialize in the medications used to treat these conditions.

There are doctors who specialize in medical conditions. Now there are pharmacists who specialize in the medications used to treat these conditions. There are doctors who specialize in medical conditions. Now there are pharmacists who specialize in the medications used to treat these conditions. A pharmacist who specializes in the medications used

More information

Session 4: Understanding Data Behind the Complex New World of Health Care Involving IDNs and ACOs. Laura Jenkins Jirele

Session 4: Understanding Data Behind the Complex New World of Health Care Involving IDNs and ACOs. Laura Jenkins Jirele Session 4: Understanding Data Behind the Complex New World of Health Care Involving IDNs and ACOs Laura Jenkins Jirele PMSA Virtual University PMSA Virtual University is conducting this four part webinar

More information

A pharmacist s guide to Pharmacy Services compensation

A pharmacist s guide to Pharmacy Services compensation Alberta Blue Cross Pharmaceutical Services A pharmacist s guide to Pharmacy Services compensation 83443 (2015/12) GENERAL DESCRIPTION... 3 Details... 3 ASSESSMENT CRITERIA... 3 Assessment for a Prescription

More information

Statement Of. The National Association of Chain Drug Stores. For. U.S. Senate Special Committee on Aging. Hearing on:

Statement Of. The National Association of Chain Drug Stores. For. U.S. Senate Special Committee on Aging. Hearing on: Statement Of The National Association of Chain Drug Stores For U.S. Senate Special Committee on Aging Hearing on: 10 Years Later: A Look at the Medicare Prescription Drug Program 2:30 p.m. 366 Dirksen

More information

The Medicare Low Income Subsidy (LIS)

The Medicare Low Income Subsidy (LIS) The Medicare Low Income Subsidy (LIS) Extra Help with Prescription Drug Costs An overview of the Medicare LIS Patient eligibility and the application process How the LIS affects patient responsibility

More information

!"#$%$&!"'()*+,-".-,/ &01*+("12"31+4156"$,+0"!*7("819".5(<(/4*<("&,5( :(()";(,-40"&,5( !"#$%$&!",/)"'()*+,5(

!#$%$&!'()*+,-.-,/ &01*+(1231+4156$,+0!*7(819.5(<(/4*<(&,5( :(();(,-40&,5( !#$%$&!,/)'()*+,5( submitted anytime during the year to your institution HR/Benefits Office, and the tobacco premium will be waived beginning the first of the month following submission of the form. Important: A member is

More information

The Standard Approach. By Steve Corby and Dave Johnson

The Standard Approach. By Steve Corby and Dave Johnson The Missing Link: Physicians and Patient Adherence How Market Research Can Offer a More Comprehensive Approach to Understanding and Solving Patient Drug Abandonment and Compliance Issues By Steve Corby

More information

November 4, 2010. Honorable Paul Ryan Ranking Member Committee on the Budget U.S. House of Representatives Washington, DC 20515.

November 4, 2010. Honorable Paul Ryan Ranking Member Committee on the Budget U.S. House of Representatives Washington, DC 20515. CONGRESSIONAL BUDGET OFFICE U.S. Congress Washington, DC 20515 Douglas W. Elmendorf, Director November 4, 2010 Honorable Paul Ryan Ranking Member Committee on the Budget U.S. House of Representatives Washington,

More information

eprescribing Information to Improve Medication Adherence

eprescribing Information to Improve Medication Adherence eprescribing Information to Improve Medication Adherence January 2014 This white paper was funded by the Pharmaceutical Research and Manufacturers of America. About Point-of-Care Partners Point-of-Care

More information

Pharmacy Outreach Program The University of Rhode Island College of Pharmacy

Pharmacy Outreach Program The University of Rhode Island College of Pharmacy Pharmacy Outreach Program The University of Rhode Island College of Pharmacy Updated October 2014 Medicare provides health insurance for Aged 65 years or older Aged 65 years or less with certain disabilities

More information

Pharmaceutical business innovation through utilization of EMR

Pharmaceutical business innovation through utilization of EMR Pharmaceutical business innovation through utilization of EMR Abstract The pharmaceutical industry in Japan is in a transformation phase due to the government s tightening control over healthcare expenditure

More information

June 23, JMP Securities Healthcare Conference

June 23, JMP Securities Healthcare Conference June 23, 2015 JMP Securities Healthcare Conference Safe Harbor Statement The following presentation includes forward-looking statements within the meaning of the safe harbor provisions of the Private Securities

More information

Overview of Specialty Pharmacy. Kevin Colgan, MA, FASHP Corporate Director of Pharmacy Rush University Medical Center

Overview of Specialty Pharmacy. Kevin Colgan, MA, FASHP Corporate Director of Pharmacy Rush University Medical Center Overview of Specialty Pharmacy Kevin Colgan, MA, FASHP Corporate Director of Pharmacy Rush University Medical Center Conflicts of Interest Chair, UHC Specialty Pharmacy Committee Wife is a Specialty Pharmacist

More information

2015 ANNUAL BENEFITS ENROLLMENT FOR PRE-65 RETIREES

2015 ANNUAL BENEFITS ENROLLMENT FOR PRE-65 RETIREES Phillips 66 2015 ANNUAL BENEFITS ENROLLMENT FOR PRE-65 RETIREES 2015 ANNUAL BENEFITS ENROLLMENT FOR PRE-65 RETIREES October 31 November 21, 2014 your HEALTH. Living well means different things to different

More information